Dashboard
Manage Tickers

CLDX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

the-analyst-verdict-celldex-therapeutics-in-the-eyes-of-7-experts
The Analyst Verdict: Celldex Therapeutics ...
09/09/2024 17:00:35

cantor-fitzgerald-reiterates-overweight-on-celldex-therapeutics-maintains-67-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:34:56

Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 p...

wells-fargo-maintains-equal-weight-on-celldex-therapeutics-raises-price-target-to-37
Wells Fargo Maintains Equal-Weight on Cell...
08/12/2024 17:45:26

Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Equal-Weight and raises the price targ...

7-analysts-have-this-to-say-about-celldex-therapeutics
7 Analysts Have This To Say About Celldex ...
08/12/2024 12:01:09

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
08/12/2024 10:07:37

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

celldex-therapeutics-q2-eps-054-beats-060-estimate-sales-250m-beat-82043k-estimate
Celldex Therapeutics Q2 EPS $(0.54) Beats ...
08/08/2024 21:08:05

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of ...

why-merck-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Merck Shares Are Trading Lower By 10%?...
07/30/2024 17:53:26

cantor-fitzgerald-reiterates-overweight-on-celldex-therapeutics-maintains-67-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/30/2024 13:58:17

Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 p...

lattice-semiconductor-posts-weak-q2-results-joins-symbotic-woodward-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Lattice Semiconductor Posts Weak Q2 Result...
07/30/2024 12:28:51

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
07/30/2024 11:46:09

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

why-f5-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket
Why F5 Shares Are Trading Higher By Over 1...
07/30/2024 09:50:34

celldex-announces-phase-2-results-for-barzolvolimab-in-chronic-inducible-urticaria-achieves-primary-endpoint-with-significant-complete-response-rates-in-both-dose-groups
Celldex Announces Phase 2 Results For Barz...
07/29/2024 20:10:05

First Large, Randomized, Placebo-Controlled Study To Demonstrate Success In CIndU; Plans Phase 3 Registration Development; Webc...

viasat--ast-spacemobile-are-among-top-6-mid-cap-stocks-that-shined-the-brightest-last-week-july-21-july-27-are-the-others-in-your-portfolio
ViaSat & AST SpaceMobile Are Among Top 6 M...
07/28/2024 18:17:42

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

analyst-expectations-for-celldex-therapeuticss-future
Analyst Expectations For Celldex Therapeut...
07/16/2024 19:01:15

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
07/16/2024 17:31:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

celldex-therapeutics-begins-global-phase-3-program-for-barzolvolimab-in-patients-with-chronic-spontaneous-urticaria
Celldex Therapeutics Begins Global Phase 3...
07/16/2024 12:03:30

cantor-fitzgerald-reiterates-overweight-on-celldex-therapeutics-maintains-67-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 13:45:01

Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 p...

wolfe-research-initiates-coverage-on-celldex-therapeutics-with-outperform-rating
Wolfe Research Initiates Coverage On Celld...
06/11/2024 18:13:38

Wolfe Research analyst Andy Chen initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Outperform rating.

analyst-expectations-for-celldex-therapeuticss-future
Analyst Expectations For Celldex Therapeut...
06/03/2024 12:00:29

hc-wainwright--co-reiterates-buy-on-celldex-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Cell...
06/03/2024 11:15:10

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION